Alex Arfaei notes he continues to be the “lone bear” on this biotech player- especially after lead pipeline asset Rova-T is no longer looking at quick approval.
Dividend Aristocrats are popular on the market because they have achieved to hike dividends over more than 25 years. A rising income is an …
This Weekend my eyes and thoughts curved around the Healthcare sector. I read several interesting articles from the sector, mostly about the biotech’s …
In a research report published Tuesday, Deutsche Bank analyst Robyn Karnauskas reiterated a Buy rating on AbbVie (NYSE:ABBV) with an $80 price target, …
